Structure–activity relationship studies on Pd176252 derivatives leading to discovery of novel GRP receptor antagonist with potent anticancer activity

Gastrin-releasing peptide (GRP)/gastrin-releasing peptide receptor (GRPR) have various physiological effects, and many studies report that GRPR is a potential anticancer target. Pd176252 is a typical small-molecule GRPR antagonist that exhibits anti-proliferation activity against most cancers. In th...

Full description

Saved in:
Bibliographic Details
Published in:Medicinal chemistry research 2021-11, Vol.30 (11), p.2069-2089
Main Authors: Yu, Ming-jun, Li, Chao, He, Meng, Zhu, Yu-ting, Yang, Rui, Deng, Sheng-song, Meng, Xiao-ming, Yao, Ri-sheng
Format: Article
Language:English
Subjects:
Anticancer properties
Antitumor activity
Apoptosis
Bcl-2 protein
Biochemistry
Biomedical and Life Sciences
Biomedicine
Bioorganic Chemistry
Cancer
Gastric cancer
Gastrin
Gastrin-releasing peptide
Hepatocellular carcinoma
Histone deacetylase
Inorganic Chemistry
Medicinal Chemistry
Molecular docking
Original Research
Pancreatic cancer
Peptides
Pharmacology/Toxicology
Physiological effects
Prostate cancer
Receptors
Tumor cell lines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastrin-releasing peptide (GRP)/gastrin-releasing peptide receptor (GRPR) have various physiological effects, and many studies report that GRPR is a potential anticancer target. Pd176252 is a typical small-molecule GRPR antagonist that exhibits anti-proliferation activity against most cancers. In this study, 31 novel Pd176252 analogues were designed, synthesized, and evaluated for anti-proliferation activity against human prostate cancer (PC3), mouse pancreatic cancer (Pan02), human gastric cancer (HGC-27), and hepatocellular carcinoma (HepG2) cell lines. Of all the compounds evaluated, 5a and 6e showed better anti-proliferation activity compared to Pd176252 against PC3 (half-maximal inhibitory concentration [IC 50 ] = 4.97 and 9.88 μM, respectively), Pan02 (IC 50  = 4.36 and 2.50 μM, respectively), and HGC-27 (IC 50  = 4.36 and 2.50 μM, respectively), cell lines. Moreover, combining 5a or 6e with a histone deacetylase (HDAC) inhibitor further improved the in vitro anti-proliferation activity. Further research showed that 5a caused HGC-27 cell apoptosis by downregulating Bcl-2 and upregulating Bax. In addition, a molecular docking analysis showed that compounds 5a and 6e could bind to GRPR. In conclusion, compounds 5a and 6e are novel GRPR antagonists with potent anticancer activity.
ISSN:1054-2523
1554-8120
DOI:10.1007/s00044-021-02793-8